ECRG2 Antibody | 6523

ECRG2 Antibody | 6523 | Gentaur UK, US & Europe Distribution

Host: Chicken

Reactivity: Human, Mouse, Rat

Homology: N/A

Immunogen: ECRG2 antibody was raised against a 16 amino acid synthetic peptide near the carboxy terminus of human ECRG2.
The immunogen is located within the last 50 amino acids of ECRG2.

Research Area: Cancer, Cell Cycle

Tested Application: E, WB, IHC-P

Application: ECRG2 antibody can be used for detection of ECRG2 by Western blot at 1 μg/mL. Antibody can also be used for immunohistochemistry starting at 5 μg/mL.
Antibody validated: Western Blot in mouse samples and Immunohistochemistry in rat samples. All other applications and species not yet tested.

Specificiy: ECRG2 antibody is predicted to not cross-react with other ECRG family members

Positive Control 1: Cat. No. 1288 - A20 Cell Lysate

Positive Control 2: N/A

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: Predicted: 9 kDa
Observed: 14 kDa

Validation: N/A

Isoform: N/A

Purification: ECRG2 Antibody is affinity chromatography purified via peptide column.

Clonality: Polyclonal

Clone: N/A

Isotype: IgY

Conjugate: Unconjugated

Physical State: Liquid

Buffer: ECRG2 Antibody is supplied in PBS containing 0.02% sodium azide.

Concentration: 1 mg/mL

Storage Condition: ECRG2 antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Alternate Name: ECRG2 Antibody: ECG2, ECRG2, ECG2, UNQ745/PRO1474, Serine protease inhibitor Kazal-type 7, Esophagus cancer-related gene 2 protein, ECRG-2

User Note: Optimal dilutions for each application to be determined by the researcher.

BACKGROUND: ECRG2 Antibody: The esophageal cancer-susceptibility gene 2 (ECRG2) , also known as SPINK7, is a novel tumor suppressor gene identified from the human esophagus. It interacts directly with metallothionein 2A and urokinase-type plasminogen activator (uPA) , and downregulates the activity of uPA, leading to reduced cancer cell migration, invasion and metastasis. ECRG2 forms a complex with uPA and its receptor uPAR, modifying the dynamic association of uPAR with beta1 integrins and disrupting the Src/MAP kinase pathway that normally stimulates cell migration and invasion. ECRG2 may thus represent a novel therapeutic target for cancer.